Press release, March 2, 2010
MEDICINE HAT BASED NUTRACEUTICAL RESEARCH GROUP QUALIFIES FOR A $50,000 ALBERTA INNOVATION VOUCHER
Medicine Hat, AB, March 2, 2010 – A local research group whose prime directive is to develop and validate the efficacy of various nutraceutical based management systems has been granted a generous $50,000 “Innovation Voucher” towards the continuation of their research and development.
Nutraceutical Research Group has developed a management system for chronic liver disease and other inflammatory based diseases, like Fibromyalgia or Chronic Fatigue Syndrome. Their products are not a cure for chronic inflammatory illness; however studies indicate they may be a very effective management system for those affected.
“We are grateful to be recognized for our work and corporate vision by the Provincial Government”, stated company founder, Todd Schneider. “We are thankful to live in a province that has the economic structure to support the vision of private enterprise. We, too, believe in the ‘Freedom to Create, and the Spirit to Achieve’, as it is this belief that makes Alberta the great province it is.”
Nutraceutical Research Group (NRG) began with the success of its founder, Todd Schneider, while searching for a therapy to regain his health, consulted with numerous world-class researchers, scientists, and clinicians. Todd arranged many meetings, facilitated connections, and nourished the formation of a team of experts. NRG emerged as a research and product development entity from this alliance of dedicated minds.
NRG works closely with Dr. Lorne Tyrrell and continues to further their research at the University of Alberta. Todd adds, “Dr. Tyrrell’s accomplishments speak for themselves and he is the perfect researcher to help further our commitment to research and development. We have also conducted research with Dr. Brent Korba at Georgetown University, under the direction of Dr. Peter Schmid, inventor of the PCR Super Quant and UltraQual. As a team, we decided to further the work of the late Dr. Charles Lieber on PPC’s (Polyenlphosphotydelcholine and therapeutic dosed Anti-Oxidants) conducted at Harvard. The results of this therapy have demonstrated consistent results, and Dr. Tyrrell states ‘He is excited about proving the mechanism of Dr. Lieber’s 30 year legacy, and furthering his work.”
For the full story contact Todd Schneider, or go to www.nutragroupinc.com